<DOC>
	<DOCNO>NCT02087098</DOCNO>
	<brief_summary>This 12 month non-interventional study solifenacin succinate , evaluate effect solifenacin quality life ( QoL ) patient previously treat antimuscarinics ( Males Females Overactive Bladder ( OAB ) symptoms withdraw treatment antimuscarinics safety and/or efficacy reason ) - measure Perception Treatment Satisfaction ( TS-VAS ) evaluate effect solifenacin quality life measure Over Active Bladder-q Short Form ( OAB-q SF ) , EuroQol Group score system ( EQ-5D-5L ) .</brief_summary>
	<brief_title>A Study Evaluate Quality Life Patients Switched Solifenacin From Other Antimuscarinics</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Patient willing able complete questionnaire Diagnosis OAB Previous unsuccessful OAB medication ( antimuscarinic treatment least 1 month ) less 4 week ago define : number micturition &gt; 8/24 h decrease urgency urinary incontinence ( UUI ) incontinence episode / 24 h less 50 % decrease urgency episodes / 24 h less 50 % decrease number micturition / 24 h less 20 % acceptable tolerability Eligible start Vesicareâ„¢ 5 10 mg accord Summary Product Characteristics ( SmPC ) History stress incontinence Active urinary tract infection ( confirm positive urine analysis ) Symptoms suggestive severe Bladder Outlet Obstruction ( BOO ) define Peak urinary flow rate ( Qmax ) &lt; 10ml/sc and/or Postvoid residual urine volume ( PVR ) &gt; 150 ml Uncontrolled Diabetes Mellitus History drug and/or alcohol abuse time enrolment History acute urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony toxic megacolon severe ulcerative colitis ) , myasthenia gravis , uncontrolled narrow glaucoma swallow anterior chamber deem risk condition . Undergoing hemodialysis severe renal impairment moderate hepatic impairment treatment potent CYP3A4 inhibitor Previous treatment solifenacin Likely participate another study study period 12 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>solifenacin</keyword>
	<keyword>quality life</keyword>
</DOC>